Eribulin mesylate for the treatment of breast cancer

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.9, 2010-06, pp. : 1587-1593

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer

By O'Sullivan Coyne Geraldine Walsh Janice Kelly Catherine M

Expert Opinion on Drug Safety, Vol. 11, Iss. 4, 2012-07 ,pp. : 643-650

Informa Healthcare

Access to resources Recommend Favorite

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration‐Resistant Prostate Cancer Treatment With Eribulin

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 7, 2015-08 ,pp. : 374-385

John Wiley & Sons Inc

Access to resources Recommend Favorite

Eribulin

By Perry Caroline M.

Drugs, Vol. 71, Iss. 10, 2011-07 ,pp. : 1321-1331

Adis International

Access to resources Recommend Favorite

Letrozole in the treatment of breast cancer

By Ellis Matthew J Shaw Heather S

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 5, 2002-05 ,pp. : 607-617

Informa Healthcare

Access to resources Recommend Favorite

Letrozole in the treatment of breast cancer

By Mouridsen Henning T Bhatnagar Ajay S

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1389-1399

Informa Healthcare

Access to resources Recommend Favorite